Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
ACS Pharmacology & Translational Science|August 23, 2021
Inhibition of Protein Synthesis Induced by CHK1 Inhibitors Discriminates Sensitive from Resistant Cancer CellsJohn W Hinds, Jennifer P Ditano, Alan EastmanOncotarget|October 22, 2021
Luminescence complementation technology for the identification of MYC:TRRAP inhibitorsEdmond J Feris, John W Hinds, Michael D ColePlos One|December 3, 2019
Formation of a structurally-stable conformation by the intrinsically disordered MYC:TRRAP complexEdmond J Feris, John W Hinds, Michael D ColePlos One|August 26, 2022
S146L in MYC is a context-dependent activating substitution in cancer developmentJohn W Hinds, Edmond J Feris, Owen M Wilkins, et al.Chemmedchem|November 10, 2012
C3'/C4'-Stereochemical Effects of Digitoxigenin α-L-/α-D-Glycoside in Cancer CytotoxicityJohn W Hinds, Sean B McKenna, Ehesan U Sharif, et al.Plos One|September 30, 2011
Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cellsJenny A Rudnick, Lisa M Arendt, Ina Klebba, et al.Cell Biochemistry and Biophysics|May 26, 2020
Selective Induction of Cellular Toxicity and Anti-tumor Efficacy by N-Methylpiperazinyl Diarylidenylpiperidone and its Pro-nitroxide Conjugate through ROS-mediated Mitochondrial Dysfunction and G2/M Cell-cycle Arrest in Human Pancreatic CancerJesse M Mast, John W Hinds, Dan Tse, et al.Cancer Biomarkers : Section a of Disease Markers|July 6, 2020
Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancerKevin Shee, John D Seigne, Margaret R Karagas, et al.The Journal of Experimental Medicine|February 14, 2018
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancerKevin Shee, Wei Yang, John W Hinds, et al.Pageof 1